TCG
NVO

Transcendent Capital Group’s Novo Nordisk NVO Stock Holding History

Transcendent Capital Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,280
Closed -$611K – 493
2024
Q2 		$611K Buy
+4,280
New +$567K 0.35% 60

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Transcendent Capital Group's NVO Position: Q3 2024 in Review

Transcendent Capital Group sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 4,280 shares — an estimated $611K sold.

Transcendent Capital Group first reported a position in NVO in Q2 2024 and held it in 1 quarter. The position peaked at $611K in Q2 2024. 1,785 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Transcendent Capital Group reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
  • Transcendent Capital Group sold 4,280 Novo Nordisk shares in Q3 2024, an estimated $611K.
  • Transcendent Capital Group first reported a position in Novo Nordisk in Q2 2024 and held it in 1 quarter.
  • Transcendent Capital Group's Novo Nordisk position peaked at $611K in Q2 2024.
  • 1,785 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Transcendent Capital Group's 13F filing for Q3 2024, filed 1 Nov 2024.